| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Completed Research
Forum: Human Proteome Folding
Thread: Researchers Identify 'Death from Cancer' Genes |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 5
|
|
| Author |
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
We are getting there.
LOS ANGELES (Reuters) - A set of 11 genes -- dubbed the "death from cancer signature" -- can identify people at the highest risk of dying from cancer, according to research presented on Tuesday. The genes are associated with cell multiplication and renewal in both stem cells and 10 different types of cancer, according to a study by a team from the Sidney Kimmel Cancer Center in San Diego. The 11 genes will alert physicians to those patients who are at much higher risk for metastatic complications and more severe cancer, Dr. Gennadi Glinksy, associate professor at the cancer center, said in a statement. The gene panel can also identify patients who are least likely to respond to conventional cancer therapies, according to the research, presented at a meeting of the American Association for Cancer Research in Anaheim, California. Early identification of these patients means that they can be directed to more aggressive, customized treatments or experimental clinical trials that they might otherwise not consider, Glinsky said. |
|||
|
||||
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
 Bump |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Thanks julied
|
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
As the actuarial statistics indicate, cancer is increasing as a leading cause of death world-wide. Many of us (myself included) have a vital interest in research such as this.
I am currently making follow-up inquiries into this research. I will post any relevant news/correspondence in a timely manner. Good luck to us all. |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
Here is a more technical article that describes some of the research paramaters (number of subjects; cancers tested; etc.) As you will read, the article states that prostate, breast, lung and ovarian cancer were 4 of the 10 cancers studied. This is quite significant.
"Death from cancer" gene signature predicts poor outcome - as reported by Reuters. Using microarray analysis, cancer researchers have identified an 11-gene signature that is strongly associated with a poor response to treatment, increased risk of metastatic spread, and shortened survival in patients with a variety of primary tumor types. The data "seem to indicate the presence of a conserved BMI-1 oncogene-driven pathway similarly engaged in both normal stem cells and a highly malignant subset of human cancers diagnosed in a wide range of organs and uniformly exhibiting a marked propensity toward metastatic dissemination as well as high probability of treatment failure," the researchers explain in an abstract of the 96th annual meeting of the American Association for Cancer Research. Early identification of cancer patients with the 11-gene so-called "death from cancer signature" will allow clinicians and patients to consider therapeutic strategies beyond the conventional at the time of diagnosis, said Dr. Gennadi V. Glinksy from the Sidney Kimmel Cancer Center in San Diego. According to the team, 93% of human and 87% of mouse tissues analyzed manifest negative (non-stem cell-like) expression profiles of the 11-gene signature. They evaluated the prognostic power of the 11-gene signature in several independent therapy outcome data sets of clinical samples obtained from 1566 cancer patients diagnosed with 10 different types of cancer: prostate, breast, lung, ovarian, bladder, lymphoma, mesothelioma, medulloblastoma, glioma, and acute myeloid leukemia. Kaplan-Meier analysis showed that a stem cell-like expression profile of the 11-gene signature in primary tumors was a "consistent powerful predictor" of a short time to disease recurrence, distant metastasis, and death after therapy. Additional studies are planned to validate these observations. If confirmed, patients with this genetic signature might be candidates for early, more aggressive individualized therapy, the investigators suggest. |
||
|
|
|